Zanubrutinib-induced liver injury: a case report and literature review
Open Access
- 29 May 2021
- journal article
- case report
- Published by Springer Nature in BMC Gastroenterology
- Vol. 21 (1) , 1-7
Abstract
Background: Zanubrutinib is a Bruton’s tyrosine kinase inhibitor that has been recently licensed in refractory mantle cell lymphoma and under assessment in phase 3 clinical trials for other B cell malignancies. To date, there are no reported cases of hepatotoxicity secondary to zanubrutinib. We report the first case of severe liver injury due to zanubrutinib. Case presentation: A 56-year-old Caucasian male with a history of relapsed lymphoplasmacytic lymphoma was admitted to the hospital with new-onset jaundice, choluria, and pruritus for 10 days. He had been on zanubrutinib as part of a clinical trial for 30 months. His blood profile showed a severe hepatocellular injury with jaundice (alanine transaminase 2474 IU/L and total bilirubin 141 umol/L with mild coagulopathy). He had an extensive work-up including virology, autoimmune, and metabolic profiles in addition to abdominal ultrasound with no alternative explanation found for his liver injury. Zanubrutinib-induced liver injury was suspected, and causality assessment by the updated Roussel Uclaf Causality Assessment Method score showed a probable causal relationship with zanubrutinib. His liver histology was also consistent with drug-induced liver injury. His liver biochemistry improved following cessation of zanubrutinib and normalised after 8 weeks. Conclusion: We report the first case of severe liver injury secondary to zanubrutinib after 30 months of treatment. This case raises clinical awareness regarding zanubrutinib-induced liver toxicity and the importance of drug withdrawal in the event of liver injury.Keywords
Funding Information
- EU-EFPIA Innovative Medicines Initiatives 2 Joint Undertaking (821283)
- National Institute of Health Research Nottingham Digestive Diseases Biomedical Research Unit and Nottingham Biomedical Research Centre (BRC-1215-20003)
This publication has 21 references indexed in Scilit:
- Rare but Serious: Ibrutinib Induced Liver FailureHemaSphere, 2019
- Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLLBlood, 2019
- Risk of hepatitis B virus reactivation in patients treated with ibrutinibBlood, 2018
- Role of Bruton’s tyrosine kinase in B cells and malignanciesMolecular Cancer, 2018
- Ibrutinib‐induced severe liver injuryClinical Case Reports, 2017
- Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literatureBMC Medicine, 2016
- A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignanciesBlood, 2016
- An investigation into drug products withdrawn from the EU market between 2002 and 2011 for safety reasons and the evidence used to support the decision-makingBMJ Open, 2014
- Hepatotoxicity of Tyrosine Kinase Inhibitors: Clinical and Regulatory PerspectivesDrug Safety, 2013
- The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injuryHepatology, 2011